Terns Pharmaceuticals, Inc. (NASDAQ: TERN)

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, operates in the healthcare sector, specifically focusing on developing small-molecule product candidates to address serious diseases such as oncology and obesity. Established in 2019, the company has already made significant strides in its field, receiving Orphan Drug Designation from the US Food and Drug Administration (FDA) for its leading product candidate, TERN-701, in the treatment of chronic myeloid leukemia (CML).

Terns Pharmaceuticals' main business activities revolve around the development of innovative small-molecule product candidates that target unmet medical needs in oncology and metabolic diseases. The company's product portfolio includes TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) for CML, TERN-601, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity, and TERN-501, a thyroid hormone receptor (THR) agonist for metabolic diseases. Additionally, Terns Pharmaceuticals is developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

The company generates revenue through the development and licensing of its product candidates to pharmaceutical companies and research institutions. Terns Pharmaceuticals' primary products include TERN-701, TERN-601, and TERN-501, which are designed to be used in combination with other therapies to treat serious diseases, including cancer and obesity.

Terns Pharmaceuticals holds a competitive advantage within the industry due to its ability to develop novel small-molecule product candidates that address unmet medical needs. The company's proprietary three-dimensional quantitative structure-activity relationship (3D QSAR) model of the receptor enables it to identify new GLP-1 receptor agonist candidates, such as TERN-601. Furthermore, Terns Pharmaceuticals' allosteric BCR-ABL TKI, TERN-701, demonstrates promise in preclinical studies, with potential to address the limitations of active-site TKIs.

Key competitors within the industry include large multinational pharmaceutical companies, established biotechnology companies, and smaller or earlier-stage biotechnology companies. Terns Pharmaceuticals' competitive edge lies in its nimbleness as a newer company, coupled with its innovative product candidates and proprietary technology.

In terms of customers, Terns Pharmaceuticals primarily serves pharmaceutical companies and research institutions interested in developing and commercializing novel small-molecule product candidates. The company's products are designed for use in combination with other therapies to treat serious diseases, including cancer and obesity.

Terns Pharmaceuticals' product brands and trade names include TERN-701, TERN-601, and TERN-501. These product candidates are in various stages of clinical trials, with TERN-701 and TERN-601 currently undergoing Phase 1 trials.